Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer

Exclusion Criteria

• •1. Patients with non-epithelial ovarian cancer or borderline ovarian tumors.
• •2. Patients with recurrent ovarian cancer who are not suitable for platinum-based chemotherapy.
• •3. Patients over 80 years of age.
• •4. Patients with a clinically assessed life expectancy of less than 3 months.
• •5. Patients deemed unsuitable for secondary cytoreductive surgery due to clinical findings (e.g., severe adhesions, bowel obstruction, fistula, perforation, or other conditions making surgery infeasible).
• •6. Patients with inadequate, cardiac, pulmonary, hepatic, renal, or bone marrow function for surgery.
• •7. Patients with uncontrolled active infections.
• •8. Patients diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), or those exhibiting features suggestive of MDS/AML.
• •9. Patients whose primary disease is an extra-abdominal condition that is expected to be a major cause of morbidity or mortality.
• •10. Patients with active central nervous system metastasis or carcinomatous meningitis. Patients with a history of brain metastasis must be radiologically stable.
• •11. Patients with infections requiring systemic treatment (parenteral administration of antibiotics for bacterial, antifungal, or antivirals).
• •12. Patients with uncontrolled active tuberculosis (TB) within one month before treatment initiation.
• •13. Patients with psychiatric disorders that may interfere with their ability to comply with the trial, including those diagnosed with mental illness or substance abuse disorders.
• •14. Female patients who have not undergone a hysterectomy and have a positive urine pregnancy test within 14 days prior to study allocation. For women of childbearing potential, even if the screening urine pregnancy test is negative, additional pregnancy tests may be conducted at the discretion of the investigator at the time of surgery or chemotherapy initiation Pregnancy tests are not required for women who have undergone hysterectomy or are otherwise confirmed to be infertile.
• •15. Patients who are currently breastfeeding.
• •16. Patients with a history of allogeneic tissue/solid organ transplantation, bone marrow transplantation, or dual umbilical cord blood transplantation.
• •17. Patients who, in the judgment of the principal investigator, are unlikely to comply with the trial procedures, restrictions, and requirements.
• •18. Patients currently enrolled in another clinical trial and receiving an investigational drugs or medical device, or those who have used any investigational drugs or device within 3 weeks prior to the first administration of the study treatment.
• •19. Patients who have entered the follow-up phase of a clinical trial may participate in this study only if at least 3 weeks have passed since their last use of an investigational drug or device.